CorFlow Therapeutics is incorporated in Baar, Switzerland, and closed it’s seed financing round on September 8th 2016. The seed round was lead by leading cardiovascular seed investors who over decades have successfully invested in innovative medical device companies such as CoreValve and CardiAQ. The round was also funded by interventional cardiology key opinion leaders. Finally, the seed round is supported by leading cardiovascular device distributors in Europe, Japan, Latin-America and China.
The company plans successive investment rounds and invites investors to contribute in bringing the CorFlow technology to market.
Feel free to contact CorFlow’s CEO, Jon H. Hoem,
+41 79 606 2 902
for further details on the upcoming financing rounds.